RedHill Biopharma (RDHL) Change in Accured Expenses (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Change in Accured Expenses data on file, last reported at -$3.2 million in Q4 2022.

• On a quarterly basis, Change in Accured Expenses fell 1151.78% year-over-year to -$3.2 million in Q4 2022; TTM through Dec 2022 was -$1.2 million, a 62.15% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, down 18.51% from the prior year.
• Change in Accured Expenses for Q4 2022 stood at -$3.2 million, down from $987000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for RDHL reached as high as $17.8 million in Q2 2020 and fell as low as -$4.7 million in Q3 2020.
• Historically, Change in Accured Expenses has averaged $732400.0 across 5 years, with a median of $213000.0 in 2018.
• Across the five-year window, Change in Accured Expenses slumped 3358.97% in 2019 and soared 6447.37% in 2020, its largest moves.
• Year by year, Change in Accured Expenses stood at $117000.0 in 2018, then slumped by 3358.97% to -$3.8 million in 2019, then soared by 149.78% to $1.9 million in 2020, then slumped by 83.72% to $309000.0 in 2021, then sank by 1151.78% to -$3.2 million in 2022.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.2 million in Q4 2022, $987000.0 in Q3 2022, and -$2.2 million in Q2 2022.